LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
Lindis Biotech GmbH / Key word(s): Regulatory Approval LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES 13.02.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLYLINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER
UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE EXCLUSIVE RIGHTS TO BRING CATUMAXOMAB TO MARKET AND TO LEAD ALL ACTIVITIES TO LAUNCH CATUMAXOMAB ACROSS EUROPE
THIS MARKS ANOTHER MILESTONE FOR PHARMANOVIA, AS IT DEEPENS ITS FOOTPRINT WITHIN SPECIALTY PHARMACEUTICALS
MUNICH, GERMANY, AND BASILDON, UK, 13 February 2025LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline in immuno-oncology, and Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.Under a licensing agreement, LINDIS has granted Pharmanovia the exclusive rights to bring catumaxomab to market and spearhead its launch across Europe.Catumaxomab, a first-in-class therapeutic, is specifically designed to treat malignant ascites in adults with certain types of cancer (epithelial cellular adhesion molecule (EpCAM)-positive carcinomas) who are not eligible for other systemic anticancer therapies. Malignant ascites is a serious complication of advanced-stage cancers, characterised by the buildup of fluid in the abdomen, causing significant discomfort and severely impacting quality of life. The condition leads to considerable symptoms such as abdominal distension, pain, shortness of breath, fatigue, and fever.Stephen Deacon, Chief Scientific Officer at Pharmanovia commented; 'This European Commission approval of catumaxomab is a significant milestone for people living with malignant ascites.Catumaxomab represents a novel therapeutic approach to this challenging condition. By targeting tumour cells and harnessing the power of the patient's own immune system, we aim to improve quality of life for those living with malignant ascites in Europe."Pharmanovia CEO, Dr. James Burt, highlighted the broader implications of the approval; 'This approval not only brings a much-needed treatment to people with malignant ascites but also exemplifies Pharmanovia's commitment to deepening our footprint within the specialty pharmaceutical sector. We are dedicated to delivering innovative and improved medicines to people in need, and this approval reinforces our position as a leader in providing access to essential therapies."Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech, added: 'We are delighted to receive marketing approval for catumaxomab. The approval highlights its potential to address the significant medical and treatment challenges faced by patients with malignant ascites. These individuals often endure invasive procedures like paracentesis, which carry risks of complications and severely impact their quality of life. Partnering with Pharmanovia to support commercialization, we are committed to ensuring that this groundbreaking therapy becomes accessible to all patients who can benefit from it.'-Ends-Notes to editorsAbout PharmanoviaPharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.Lindis BiotechLindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases.About CATUMAXOMABCatumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons.On 17th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®.Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body's immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect. ,The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial cancer) and is also known as a marker on tumor initiating cancer stem cells – a main driver of metastasis. Therefore, it is a promising approach for targeted treatment of various carcinomas.For more information please contact: Pharmanovia Alison Dyson Director of Communications, Pharmanovia Tel.: 07912887250 E-Mail: orLINDIS Biotech GmbH Dr. Horst Lindhofer CEO E-Mail: Website:Media inquiries MC Services AG Anne Hennecke Tel.: +49 (0) 211-529-252-22 E-Mail:References Korjuny | European Medicines Agency (EMA) (2024) European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny (Accessed: 11 December 2024). Ascites and Cancer - Side Effects (2024) Cancer.gov. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/ascites#signs-and-symptoms-of-ascites (Accessed: 11 December 2024). Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1–10; 2013
13.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Canada to hit NATO spending target this year as it shifts defense focus toward EU
Canada will reach NATO's defense spending target of 2% of GDP this year, five years ahead of schedule, Prime Minister Mark Carney announced on June 9. Speaking at the University of Toronto, Carney said the move is part of a strategic pivot away from reliance on the U.S. and toward deeper cooperation with the European Union, citing growing security threats from Russia, China, and other adversaries. Carney said Canada's current military capabilities are inadequate, noting that only one of four submarines is operational and much of the maritime and land fleet is outdated. To reverse this trend, his government is launching a $6.8 (9.3 billion Canadian dollars) boost to the defense budget for 2025-26. The investment will be tabled in Parliament through supplementary estimates and directed toward rebuilding the Canadian Armed Forces, upgrading equipment, and expanding domestic production capabilities. The new defense posture includes reassessing major procurement decisions, such as the planned purchase of U.S.-made F-35 jets, and prioritizing partnerships with European firms for equipment acquisitions. Carney emphasized that three-quarters of Canada's defense capital spending has gone to the U.S., a pattern he said must end. "We're doing this for us," Carney was quoted as saying. "Relatedly we're doing it as a strong NATO partner, we're a firm believer in NATO, and we're standing shoulder to shoulder with our NATO allies, we'll continue to do so. ." Carney's announcement comes just ahead of the NATO leaders' summit in late June, where member states are expected to commit to higher defense spending thresholds of up to 5%. The prime minister said Canada would support a new NATO defense industrial pledge and participate in the EU's ReArm Europe initiative. He added that future cooperation with the EU will be a major theme of the upcoming Canada-EU summit. Read also: Ukraine war latest: Ukraine shoots down nearly 500 drones, missiles in Russian record strike, Air Force says We've been working hard to bring you independent, locally-sourced news from Ukraine. Consider supporting the Kyiv Independent.
Yahoo
39 minutes ago
- Yahoo
Five things to know about Canada's plan to meet the NATO defence spending target
OTTAWA — Prime Minister Mark Carney is promising that Canada will quickly boost its defence spending to hit the NATO member target of two per cent of national GDP this year. Canada has long promised to meet the target but has never had a detailed plan to get there. The announcement comes as NATO allies prepare for talks on raising the spending target to five per cent at the annual summit this month. Here's what you need to know about the announcement. 1. What is the NATO spending target? All NATO allies, Canada included, committed to spending the equivalent of two per cent of their GDP on defence in 2006. In 2014, NATO leaders agreed formally that countries that were not meeting the target must move toward it within a decade. After Russia launched its full-scale invasion of Ukraine in 2022, allies agreed at the 2023 NATO summit to make two per cent the minimum spending target. Many European countries have rapidly scaled up their defence spending in response to Russia's war on Ukraine. As of this year, 22 of the 32 NATO member states are spending at least two per cent of their national GDP on defence. Canada is not among them. A leaked Pentagon document obtained by The Washington Post in 2023 quoted then-prime minister Justin Trudeau telling NATO officials that Canada would not meet the two per cent target. Under pressure from allies, the Trudeau government later promised to hit the two per cent benchmark by 2032. In January, then-defence minister Bill Blair told reporters he was trying to speed up that timeline to 2027. 2. Why is the target changing? At this year's NATO leaders' summit in The Hague, allies will discuss a proposal to boost the spending target to five per cent of GDP. That's expected to be broken down into two parts — 3.5 per cent for what NATO calls core defence spending and another 1.5 per cent for a broader category of defence and security-related spending. NATO Secretary-General Mark Rutte told reporters last week there was "broad support" among allies for the change and that he had total confidence they would agree to it at the summit, which is being held June 24-26. The change is seen as a response to U.S. President Donald Trump's demands for allies to pull more weight in NATO. Among NATO members, the U.S. spends the most on its military in dollar terms. In March, Trump suggested America might not defend its allies if they don't meet the target. "If they don't pay, I'm not going to defend them," he said. According to NATO's most recent figures, U.S. defence spending was estimated at 3.19 per cent of GDP in 2024, down from 3.68 per cent a decade ago. It's the only NATO ally whose defence spending has dropped since 2014. 3. How much is Canada spending on defence? According to the latest NATO projections, Canada was on track to spend 1.45 per cent of GDP on defence in 2024-25. NATO allies also have agreed that 20 per cent of their spending should go toward equipment. In 2024, Canada was on track to spend 17.8 per cent of its total on equipment, making it one of only three countries to miss both parts of the target. Carney's announcement on Monday amounts to another $9.3 billion in spending in this fiscal year, 2025-26. Senior government officials told reporters at a briefing Monday morning that the country's defence spending for the fiscal year was projected to be $53.4 billion. With the announcement of this new spending, that sum is expected to rise to $62.7 billion for 2025-26 — or two per cent of Canada's national GDP, which is estimated at just over $3.1 trillion this year. While most of that — $53.4 billion — is Department of National Defence spending, about $14 billion is going to other government departments, including $370 million for the Communications Security Establishment. 3. What is the money being spent on? A large amount of the spending announced on Monday — $2.63 billion — is meant to "empower the military to recruit and retain the personnel needed to carry out its mandate," said a Government of Canada press release. The government says that funding will help accelerate military recruitment and expand the civilian defence workforce. It includes a pay raise for members. The Canadian Armed Forces is short more than 13,000 personnel in its regular and reserve forces. In February, Chief of the Defence Staff Gen. Jennie Carignan said the Armed Forces was on track to meet its recruitment goal of enrolling 6,496 members this fiscal year. The military said it was aiming to reach its approved strength of 71,500 regular forces members and 30,000 reserve members by April 2029. Another $2.1 billion is set aside to diversify Canada's defence partnerships and help build the domestic defence industry. Carney has said Canada wants to join ReArm Europe, an 800 billion-euro plan to beef up the defence of EU countries. Government officials said Monday that $2.1 billion could help Canada enter joint procurements or multilateral initiatives with other countries. 5. What is happening with the Coast Guard? The government is planning to include $2.5 billion it spends on the Canadian Coast Guard in its NATO spending this year — about 60 per cent of the agency's total budget. The Coast Guard will remain part of the Department of Fisheries and Oceans. It's responsible for ensuring the safety of people in Canadian waters, carrying out search-and-rescue operations and conducting research, and has a fleet of icebreakers. The Coast Guard also has a mandate to "ensure Canada's sovereignty and security by establishing a strong federal presence in our waters," according to the Government of Canada. Government officials said there is no plan to arm the Coast Guard or its members. They say its inclusion in Canada's overall defence and security strategy reflects its role in providing what they call maritime domain awareness. The intent, officials told reporters, is to improve inter-service communication, particularly in the Arctic region. The increased co-operation could involve sending military members on Coast Guard trips, for example. The government said it's boosting the Coast Guard budget by $100 million. — With files from Kyle Duggan and The Associated Press This report by The Canadian Press was first published June 9, 2025. The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trump may have to choose: Making trade deals or keeping his car tariffs
President Donald Trump is telling domestic audiences he won't cut his 25 percent tariffs on foreign cars as part of any trade deals he negotiates. But other countries — who collectively send millions of vehicles to the U.S. each year — haven't gotten that message. Trading partners like the EU, Japan and South Korea are laboring under the impression that the auto tariffs, which Trump imposed in April, are still on the table, according to two people familiar with the talks between Trump officials and those countries, granted anonymity to discuss private conversations. If Trump is really unwilling to lower or eliminate his tariffs on foreign cars, it could prove to be a major hurdle to securing meaningful trade deals with some of the country's top trading partners. Japan, South Korea and Germany sold more than $121 billion in cars and car parts in the U.S. in 2024. The White House did not answer when asked if auto tariffs were on the table for negotiations and instead reiterated the goal of the tariffs. 'No president has taken a greater interest in reviving America's once-dominant auto industry than President Trump, and the auto industry is a key focus of the Trump administration's trade and economic policies,' said Kush Desai, a White House spokesperson. 'Discussions with our major trading partners continue, and the Trump administration continues to seek better trade deals for American industries and workers.' A decision to lift the tariffs for more countries, particularly those whose companies compete most fiercely with American carmakers, risks alienating a powerful manufacturing bloc and undercutting a central tenet of Trump's trade agenda — forcing companies to build more products in the U.S. The Trump administration has assured American automakers that when it comes to auto tariffs being used as a bargaining chip, they have 'nothing to worry about,' according to a person familiar with discussions between the administration and Detroit's 'Big Three' auto companies, granted anonymity because of the sensitive nature of the talks. Trump has said a deal to lower the tariff on a small number of British cars, announced last month, was an exception. 'I won't do that deal with cars' for other countries, Trump said when announcing the terms of negotiation with the U.K. on May 8. The British auto brand Rolls-Royce is 'a very special car and it's a very limited number too. It's not one of the monster car companies that makes millions of cars,' he noted. Even that agreement, which lowered the tariff on 100,000 cars, less than 1 percent of total U.S. annual car sales, drew a sharp rebuke from U.S. automakers. 'This hurts American automakers, suppliers, and auto workers,' the American Automotive Policy Council, which represents General Motors, Ford and Stellantis, said at the time, saying they hoped it 'does not set a precedent for future negotiations with Asian and European competitors.' The tension between the two goals — boosting domestic auto production while also negotiating delicate agreements to lower trade barriers — highlights the challenge facing the administration as it races to secure deals with dozens of countries before the president's double-digit 'reciprocal' tariffs are slated to kick back in next month. 'To ease the sting of those tariffs on the auto sectors for Korea and Japan is of course a high priority for them,' said Michael Beeman, a former assistant U.S. trade representative who focused on Japan and South Korea. 'I think for those countries, to be able to declare success from the talks at home, they would expect some sort of consideration." The auto tariffs have already been a sticking point in negotiations with Japan and South Korea, both of which are invested in maintaining a high level of domestic auto manufacturing. Auto exports from South Korea to the U.S. have exploded over the past 20 years, from $8.7 billion in 2005 to $37.3 billion in 2024, according to data collected by the Census Bureau. Japanese Prime Minister Shigeru Ishiba has said publicly that any trade deal with Japan would have to result in lower auto tariffs. Now, as the two countries are on their fifth round of talks, with a planned meeting between Ishiba and Trump at the G7 in Canada in two weekends, both countries are projecting optimism about a deal. "I think we'll also need to address, at a minimum, the auto [Section] 232 tariffs,' said Wendy Cutler, a former negotiator with the U.S. trade representative's office and the vice president at the Asia Society Policy Institute, said when asked what it would take to get a deal with Japan. Cutler said any deal with Japan or South Korea could have a lower tariff for a certain number of vehicles, similar to the deal with the U.K. Or, 'they could also just be very vague and say that the U.S. notes Japan's concern on the auto tariffs, and both sides agree to negotiate possible lowering of the tariffs in this detailed negotiation to follow," she said. Trump has already agreed to lower tariffs on automobiles once. In his first trade agreement since imposing a global 10 percent tariff on nearly every U.S. trading partner and potentially higher rates on more than 60 countries, Trump struck an agreement with the U.K. that would allow the country to ship 100,000 vehicles into the country at a 10 percent tariff — lower than the current 25 percent tariff on automobiles and auto parts. The deal drew condemnation from American automakers, who noted that it meant a lower tariff on cars imported from the U.K. than on North American-made cars that include U.S.-made parts. They expressed concern that lowering tariffs with major auto manufacturing countries like Japan, South Korea and Germany would make it more expensive to build cars with parts from North America — creating an unfair playing field and effectively undercutting the administration's effort to boost domestic auto manufacturing. Vehicles made across the integrated North American supply chain still face a 25 percent tariff on non-U.S. made content, even if the vehicle is compliant with the U.S.-Mexico-Canada trade agreement that Trump negotiated in his first term. The Trump administration has continued to press foreign automakers to move production to the U.S. Last week, Trump met with German automakers, who offered $100 billion in investment in the U.S., according to Commerce Secretary Howard Lutnick. Trump — and Republicans on Capitol Hill — say those commitments are a sign that tariffs are working. "They make BMWs in South Carolina, Volvo. They make Mercedes in Alabama,' Sen. Lindsey Graham (R-S.C.) pointed out during a Senate Appropriations Committee hearing Wednesday. Under Trump, 'They're talking about making the engine now in South Carolina. They're talking about more content in South Carolina.' There has yet to be an uptick in U.S. auto manufacturing, however, a reminder that the investment pledges will take years to fully develop. Auto manufacturing jobs held steady between April and May, though there were 2,240 fewer auto manufacturing jobs in May, compared to 2024, according to the Bureau of Labor Statistics. While welcoming the announcements, the Trump White House has given no indication the investment pledges will convince the president to lower auto tariffs on foreign countries. 'I mean, unless somebody shows me that there's another kind of a car that's comparable to a Rolls-Royce,' Trump said in May, 'and there aren't too many.'
